SKI Market

Indian Indices

Nifty

25,492.30 -17.40
(-0.07%)

Sensex

83,216.28 -94.73
( -0.11%)

Bank Nifty

57,876.80 322.55
( 0.56%)

Nifty IT

35,117.65 -219.95
( -0.62%)

Global Indices

Nasdaq

16.76 83.45
(0.18%)

Dow Jones

6,751.11 9.79
(0.15%)

Hang Seng

50,211.07 -672.61
(-1.32%)

Nikkei 225

9,688.02 -47.76
(-0.49%)

Forex

USD-INR

88.62 -0.02
(-0.03%)

EUR-INR

102.12 0.31
(0.30%)

GBP-INR

116.02 0.48
(0.42%)

JPY-INR

0.58 0.00
(0.14%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Marksans Pharma Ltd

Industry : Pharmaceuticals - Indian - Formulations

BSE Code

ISIN Demat

Book Value()

524404

INE750C01026

30.5295026

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

MARKSANS

40.52

8281.57

EPS(TTM)

Face Value()

Div & Yield %

4.51

0.44

Back

Elantas Beck India standalone net profit rises 16.70% in the September 2025 quarter

Nov 05,2025

Net profit of Elantas Beck India rose 16.70% to Rs 36.26 crore in the quarter ended September 2025 as against Rs 31.07 crore during the previous quarter ended September 2024. Sales rose 17.97% to Rs 216.55 crore in the quarter ended September 2025 as against Rs 183.57 crore during the previous quarter ended September 2024.

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	216.55	183.57	18
OPM %	21.79	18.06	-
PBDT	54.23	45.47	19
PBT	48.56	41.61	17
NP	36.26	31.07	17

25,492.30 -17.40 (-0.07%)

83,216.28 -94.73 ( -0.11%)

57,876.80 322.55 ( 0.56%)

35,117.65 -219.95 ( -0.62%)

16.76 83.45 (0.18%)

6,751.11 9.79 (0.15%)

50,211.07 -672.61 (-1.32%)

9,688.02 -47.76 (-0.49%)

88.62 -0.02 (-0.03%)

102.12 0.31 (0.30%)

116.02 0.48 (0.42%)

0.58 0.00 (0.14%)